These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18987562)

  • 1. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
    Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
    Kugaya A; Sanacora G; Staley JK; Malison RT; Bozkurt A; Khan S; Anand A; Van Dyck CH; Baldwin RM; Seibyl JP; Charney D; Innis RB
    Biol Psychiatry; 2004 Oct; 56(7):497-502. PubMed ID: 15450785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.
    Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH
    Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder.
    Simoons M; Mulder H; Appeldoorn JTY; Risselada AJ; Schene AH; van Schaik RHN; van Roon EN; Ruhé EG
    Psychiatr Genet; 2020 Feb; 30(1):19-29. PubMed ID: 31634334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder.
    Ruhé HG; Koster M; Booij J; van Herk M; Veltman DJ; Schene AH
    Psychiatry Res; 2014 Feb; 221(2):155-61. PubMed ID: 24406081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.
    Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K
    Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study.
    Catafau AM; Perez V; Plaza P; Pascual JC; Bullich S; Suarez M; Penengo MM; Corripio I; Puigdemont D; Danus M; Perich J; Alvarez E
    Psychopharmacology (Berl); 2006 Dec; 189(2):145-53. PubMed ID: 17033844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
    Tomita T; Yasui-Furukori N; Nakagami T; Tsuchimine S; Ishioka M; Kaneda A; Sugawara N; Kaneko S
    PLoS One; 2014; 9(5):e98099. PubMed ID: 24858363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
    Manoharan A; Shewade DG; Rajkumar RP; Adithan S
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1215-1220. PubMed ID: 27439447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.
    Bozina N; Peles AM; Sagud M; Bilusic H; Jakovljevic M
    World J Biol Psychiatry; 2008; 9(3):190-7. PubMed ID: 17853254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.
    Lotrich FE; Pollock BG; Kirshner M; Ferrell RF; Reynolds Iii CF
    J Psychiatry Neurosci; 2008 Mar; 33(2):123-30. PubMed ID: 18330458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin transporter polymorphism and bleeding time during SSRI therapy.
    Hougardy DM; Egberts TC; van der Graaf F; Brenninkmeijer VJ; Derijks LJ
    Br J Clin Pharmacol; 2008 May; 65(5):761-6. PubMed ID: 18279474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.
    Jarčušková D; Tkáč I; Hlaváčová N; Yaluri AS; Kozárová M; Habalová V; Klimčáková L; Židzik J; Javorský M; Bednářová A
    BMC Psychiatry; 2024 Oct; 24(1):690. PubMed ID: 39407134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.
    Owens MJ; Krulewicz S; Simon JS; Sheehan DV; Thase ME; Carpenter DJ; Plott SJ; Nemeroff CB
    Neuropsychopharmacology; 2008 Dec; 33(13):3201-12. PubMed ID: 18418363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.
    Smits K; Smits L; Peeters F; Schouten J; Janssen R; Smeets H; van Os J; Prins M
    Int Clin Psychopharmacol; 2007 May; 22(3):137-43. PubMed ID: 17414739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
    Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
    JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
    Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
    Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
    Won ES; Chang HS; Lee HY; Ham BJ; Lee MS
    Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.